SCHEMBL6110290

SCHEMBL6110290

COc1cc(NC(=O)Nc2ccc(OC(F)(F)F)cc2Br)ccc1C(=O)O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCHR1 Q99705 3/20 0.68
▸ KDR P35968 1/20 0.55
▸ ALDH1A1 P00352 3/20 0.52
▸ POLB P06746 2/20 0.52
▸ GAA P10253 2/20 0.52
▸ THRB P10828 2/20 0.52
▸ MEN1 O00255 4/20 0.47
▸ KMT2A Q03164 4/20 0.47
▸ EPHX2 P34913 2/20 0.47
▸ MAPT P10636 6/20 0.47
▸ GRIK1 P39086 1/20 0.47
▸ KDM4E B2RXH2 3/20 0.46
▸ FAAH O00519 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ RCE1 Q9Y256 1/20 0.45
▸ LMNA P02545 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6110071 0.93 MCHR1 (0.69) MCHR1KDRALDH1A1POLBGAA
SCHEMBL6108536 0.88 MCHR1 (0.64) MCHR1KDRALDH1A1GAAMEN1
SCHEMBL6108209 0.82 MCHR1 (1.00) MCHR1
SCHEMBL1972074 0.79 ALDH1A1 (0.54) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL6110250 0.76 MCHR1 (0.63) MCHR1KDRALDH1A1EPHX2GRIK1
SCHEMBL11536864 0.75 CYP1A2 (0.73) MCHR1ALDH1A1GAAKMT2AMAPT
SCHEMBL6141015 0.75 MCHR1 (0.65) MCHR1MEN1KMT2AEPHX2MAPT
SCHEMBL9475099 0.74 POLB (0.65) MCHR1KDRALDH1A1POLBGAA
SCHEMBL987280 0.73 KDM4E (0.51) ALDH1A1POLBMAPTKDM4EHPGD
SCHEMBL6110029 0.73 MCHR1 (0.65) MCHR1KDRALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060235035-A1 Novel methoxybenzamibe compounds for use in mch receptor related disorders 7TM PHARMA A/S (DK) 2006-10-19 — — US disclosed
EP-1497260-A1 NOVEL METHOXYBENZAMIDE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS 7TM Pharma A/S (DK) 2005-01-19 — — EP disclosed
WO-2004048319-A1 NOVEL BENZAMIDE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS 7TM PHARMA A/S (DK) 2004-06-10 — — WO disclosed
WO-2003087045-A1 NOVEL METHOXYBENZAMIDE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS 7TM PHARMA A/S (DK) 2003-10-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060235035-A1 Novel methoxybenzamibe compounds for use in mch receptor related disorders GPR119, MCHR2, HCRTR2 MCHR1 5/4885KDR 1771/4885ALDH1A1 3618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback